Brief: Palisade Bio Announces Topline Results From U.S. Phase 2 Profile Study Evaluating LB1148 For Post-Surgical Abdominal Adhesions

Palisade Bio

09/08/2023 15:14

Aug 9 (Reuters) - Palisade Bio Inc  PALI.O :
    * PALISADE BIO ANNOUNCES TOPLINE RESULTS FROM U.S. PHASE 2
PROFILE
STUDY EVALUATING LB1148 FOR POST-SURGICAL ABDOMINAL ADHESIONS
    * PALISADE BIO INC - DOES NOT BELIEVE SAFETY DATA AND
EFFICACY
RESULTS OF PHASE 2 PROFILE TRIAL SUPPORT FURTHER DEVELOPMENT OF
LB1148
    * PALISADE BIO- STUDY DID NOT ACHIEVE PRIMARY EFFICACY
ENDPOINT
    * PALISADE BIO INC - THERE WERE 30 SERIOUS ADVERSE EVENTS ,
WITH
16 SAES REPORTED IN LB1148 GROUP (3 RELATED TO LB1148) VERSUS 14
IN PLACEBO GROUP

Source text for Eikon:  ID:nGNX6C6dBt 
Further company coverage:  PALI.O